AiVF is a technology company.
AiVF has raised $26.0M across 2 funding rounds.
AiVF has raised $26.0M in total across 2 funding rounds.
AiVF has raised $26.0M in total across 2 funding rounds.
AiVF's investors include Acrew Capital, Andreessen Horowitz, B Capital Group, Coalition Operators, Cowboy Ventures, Equity Venture Partners, Hack VC, Insight Partners, Sequoia Capital, Struck Capital, Uncork Capital, Y Combinator.
AiVF is an Israeli technology company revolutionizing in vitro fertilization (IVF) through artificial intelligence, developing the EMA platform to automate embryo assessment and improve clinic efficiency.[1][2] It serves fertility clinics, labs, and patients worldwide by addressing key IVF challenges like high costs, low success rates, and growing demand—projected to enable one billion births by century's end—via AI-driven tools that are 50 times faster and 48% more accurate than human embryologists.[1][2] The platform boosts pregnancy rates (up to 30% per frozen transfer in user clinics), reduces cycles needed, and enhances predictability, with EMA holding CE Mark and compliance with GDPR and HIPAA.[2][3]
AiVF was founded in 2018 by Daniella Gilboa, a clinical embryologist pursuing her PhD, and Prof. Daniel Seidman, a reproductive medicine expert.[1][2] The idea emerged from Gilboa's thesis, where she identified data science's potential to transform IVF's subjective, manual processes—sparking the creation of EMA, the first fully AI-based embryo grading platform using machine learning and computer vision.[1][2] Early traction came from real-world adoption in Europe, the US, and Australia, with clinics reporting superior outcomes like 65% implantation rates for high-scoring embryos, humanizing the mission to make parenthood more accessible.[1][3]
AiVF stands out in the IVF tech space through these key strengths:
AiVF rides the AI-in-healthcare wave, specifically digitizing reproductive medicine amid soaring IVF demand—millions of babies born since 1978, yet traditional methods lag in efficiency and scalability.[1][2] Timing aligns with post-pandemic fertility surges, aging populations, and AI advancements in computer vision, positioning AiVF to democratize access in a market strained by costs and subjectivity.[1][3] It influences the ecosystem by partnering with clinics (e.g., Perfetto), fostering AI adoption in labs, and setting standards for non-invasive embryo selection—backed by investors like Altaroc's Odyssey 2021 fund—accelerating IVF's evolution toward predictive, patient-centric care.[1][3]
AiVF is poised for expansion with EMA's validated edge, targeting more clinics amid IVF's global boom and AI's maturation in medtech. Trends like personalized medicine, automation in labs, and regulatory tailwinds (e.g., further FDA nods) will propel growth, potentially capturing share in a multi-billion-dollar market.[1][2][3] Influence may evolve through deeper integrations, broader AI suites for IVF workflows, and ecosystem leadership—echoing its origin as a thesis-born disruptor now empowering family dreams at scale.[1][2]
AiVF has raised $26.0M across 2 funding rounds. Most recently, it raised $25.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $25.0M Series A | Acrew Capital, Andreessen Horowitz, B Capital Group, Coalition Operators, Cowboy Ventures, Equity Venture Partners, Hack VC, Insight Partners, Sequoia Capital, Struck Capital, Uncork Capital, Y Combinator, John Kobs, Mathilde Collin, Michael Ma, Michael Stoppelman, Russ Heddleston | |
| Apr 1, 2021 | $1.0M Seed | Banana Capital, Muchmore Ventures, Polychain Capital, Socially Financed, Streamlined Ventures, Anthony Pompliano, Ian Borthwick, Trevor McFedries |